For decades, pancreatic cancer has been oncology’s most formidable wall. On Monday, a California biotech company reported that it may have finally broken through.

Revolution Medicines’ experimental drug daraxonrasib nearly doubled survival in patients with metastatic pancreatic cancer compared to standard chemotherapy in a Phase 3 trial. Patients taking the once-daily pill lived a median of 13.2 months versus 6.7 months for those receiving intravenous chemotherapy — a hazard ratio of 0.40, meaning the drug cut the risk of death by roughly 60 percent.

The results, from a trial called RASolute 302, met all primary and secondary endpoints. Revolution described the overall survival benefit as “unprecedented” for a Phase 3 pancreatic cancer trial. The trial’s principal investigator, Dr. Brian Wolpin of Dana-Farber Cancer Institute, said he expects the findings to be “practice-changing.”

Why pancreatic cancer has resisted every advance

Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, is a uniquely cruel diagnosis. Roughly 80 percent of patients are diagnosed after the disease has already spread beyond the pancreas, when surgery is often no longer an option.

The five-year survival rate for metastatic pancreatic cancer sits at approximately 3 percent, according to Revolution Medicines, citing recent US estimates. Across all stages, the rate reaches roughly 13 percent — still the lowest of any major cancer. About 60,000 Americans are diagnosed annually and approximately 50,000 die from the disease, per the company’s press release.

Standard treatment has barely budged in years: intravenous chemotherapy that extends life by weeks or a few months, often with punishing side effects.

What daraxonrasib does differently

More than 90 percent of pancreatic cancers harbor mutations in RAS genes, which drive aggressive tumor growth. Revolution describes pancreatic cancer as the most “RAS-addicted” of all major cancers. For decades, RAS proteins were considered essentially undruggable — their smooth structure offered no obvious foothold for a drug to bind.

Daraxonrasib takes a different approach. It is a multi-selective, non-covalent inhibitor of what scientists call RAS(ON) proteins — the active form of RAS that signals cells to divide. Rather than targeting a single mutation, it is designed to block a broad spectrum of RAS variants. The drug is taken orally once daily at a 300 mg dose.

This breadth matters because pancreatic tumors carry a wide range of RAS mutations — G12D, G12V, G12R, and others. A drug targeting only one variant would help a fraction of patients. Daraxonrasib was tested across patients with various RAS mutations and those without an identified mutation, and improved survival across the entire study population.

The trial enrolled patients whose cancer had already progressed on prior treatment. For this group, options have been vanishingly scarce.

What stands between these results and patients

A Phase 3 win is a milestone, not a finish line. Daraxonrasib has not been approved by any regulatory authority. Revolution plans to submit a New Drug Application to the FDA using a Commissioner’s National Priority Voucher — a pilot program that can compress the standard 10-to-12-month review timeline to as little as one to two months, according to BioSpace.

The company also intends to file with other global regulators and will present detailed results at the American Society of Clinical Oncology Annual Meeting in late May.

Safety data so far are encouraging. Revolution reported a “manageable safety profile” with no new safety signals. Rash is a known side effect — former US Senator Ben Sasse publicly described experiencing it while taking the drug in a New York Times interview last week. Revolution CEO Dr. Mark Goldsmith told CNBC the rash is “generally manageable.”

Revolution is already running additional Phase 3 trials, including one testing daraxonrasib in newly diagnosed pancreatic cancer patients, both alone and combined with chemotherapy. Competition is also in motion: Immuneering reported in January that its drug atebimetinib showed a 64 percent overall survival rate at 12 months in first-line pancreatic cancer patients.

Analysts at Evaluate rated daraxonrasib the most valuable orphan drug in development across biopharma last month, projecting $4 billion in annual sales by 2032 — a measure of the unmet need this drug aims to address.

The company’s shares surged more than 30 percent on Monday’s news.

For a disease that has frustrated generations of oncologists, the math is stark: 13.2 months versus 6.7 months. Daraxonrasib is not a cure. But for patients told there is almost nothing left to try, the gap between those numbers represents something pancreatic cancer has rarely offered — meaningful, additional time.

Sources